News

This study further strengthens the link between a history of carpal tunnel syndrome and amyloidosis.

Researchers found increased incidence and prevalence of ATTR amyloidosis driven largely by the transthyretin amyloid cardiomyopathy (ATTR-CM).

Sex-specific differences in ATTR-CM may lead to diagnostic delays in women, compromising long-term outcomes.

Research indicates that individuals who provide care for patients with ATTR-CM often experience significant challenges on their own.

A small but important number of people develop ATTR-CM before age 65 and often have early symptoms that are not limited to the heart.

Real-world evidence shows that new targeted therapies significantly reduce mortality in patients with ATTR-CM.

Researchers interviewed patients with or at risk for ATTR-CM to understand how patient experiences relate to quality of life.

In a phase 2 trial, the investigational antibody treatment coramitug produced a meaningful biomarker improvement in people with ATTR-CM.

Family genetic screening for hereditary ATTR found many carriers and showed that early testing can lead to diagnosis at younger ages.

Intellia Therapeutics paused two phase 3 trials of its CRISPR-based therapy after a patient developed severe liver toxicity.